AstraZeneca Pharma India Releases Sustainability Report Highlighting Climate Action and Resource Efficiency

AstraZeneca Pharma India Releases Sustainability Report Highlighting Climate Action and Resource Efficiency​

AstraZeneca Pharma India Limited has released its Business Responsibility and Sustainability Report for the financial year ended March 31, 2026. The report details the company's commitment to sustainable business practices across climate action, resource management, and human capital development, with the findings being assured by KPMG Assurance and Consulting Services LLP.

The report provides a comprehensive look at operational performance, emphasizing the interconnection between planetary health and public well-being within the pharmaceutical sector.

Operational and Business Profile​

AstraZeneca Pharma India operates primarily in the marketing and trading of pharmaceutical products, accounting for 90% of its turnover on a standalone basis. The company maintains a portfolio of 12 total locations across national operations, including 4 offices.

In terms of global reach, the company serves markets both nationally and internationally (Nepal). Export sales contributed ₹ 1,175.6 million to the entity's total turnover of ₹ 22,755.8 million, representing a share of 5.2%.

Climate Action and Energy Footprint​

The sustainability review highlighted significant strides in climate action. AstraZeneca Pharma India achieved an 88% reduction in Scope 1 and Scope 2 emissions since 2015, alongside doubling its revenue. The company views climate mitigation as a key opportunity to advance sustainable patient care.

In terms of energy usage, the total energy consumed during FY 2025-26 was 10,477.20 GJ, down from 22,927.55 GJ in FY 2024-25. The energy intensity per rupee of turnover for the company stood at 0.46 GJ/₹ million.

Resource Management and Waste Control​

The organization focused on efficient resource consumption and waste management across its operations.

Resource Usage Metrics (FY 2025-26 vs FY 2024-25):


The company successfully managed its waste streams, generating a total waste of 10.89 metric tonnes in FY 2025-26, a reduction from 26.26 metric tonnes the previous year. The waste intensity per rupee of turnover was reported as 0.0005 metric tonne/₹ million.

Regarding liquid discharge, the company confirmed that generated effluent is 100% treated in-house via a Combined Effluent Treatment Plant and is utilized within the manufacturing facility for landscaping purposes.

People and Governance​

The company employed 760 permanent employees during FY 2025-26, comprising 558 male employees (73%) and 202 female employees (27%). The organization has a formal Grievance Redressal Policy and utilizes an AZ Ethics portal for grievance reporting.

The report highlighted commitments to internal development:

• Training: A total of 14 training programs were conducted for the Board of Directors and Key Managerial Personnel (KMP), achieving 100% coverage. Similarly, all employees achieved a 100% coverage rate in relevant training areas like Security and Data Privacy.
• Wellbeing Spending: The cost incurred on well-being measures as a percentage of total revenue stood at 0.41% for FY 2025-26, down from 0.48% in FY 2024-25.
• Fair Pay: Gross wages paid to female employees totaled 25.54% of the entity's total wages in FY 2025-26, showing an increase from 19.88% in FY 2024-25.

The company confirmed that all permanent employees and workers are covered by Provident Fund (PF) and Gratuity benefits. The organization also stated that it adheres to all applicable environmental laws and holds the necessary consents from the KSPCB regarding hazardous and biomedical waste authorization.

ASTRAZEN Stock Price Movement​

Shares of AstraZeneca Pharma India Limited slipped on Friday, closing at ₹8023.5 after shedding ₹65.50 or 0.81% during trading. The stock saw a daily trading range between ₹7933 and ₹8170 and recorded a volume of 8,914 shares for the session.